Midatech Pharma PLC is a globally renowned biotechnology company focused on developing innovative therapeutic solutions. With a strong commitment to advancing patient care, Midatech Pharma PLC prioritizes values of excellence, integrity, and scientific rigor in its operations. The company's corporate philosophy revolves around leveraging unique drug delivery technologies to improve the effectiveness and targeting of therapies. Midatech Pharma PLC's dedication to precision medicine and personalized treatment approaches sets it apart in the healthcare industry. By aligning innovation with patient needs, Midatech Pharma PLC strives to make a significant impact on the lives of individuals globally.

Midatech Pharma PLC is primarily present in the United Kingdom, United States, and Spain. Their presence is also notable in other European countries such as Germany and France. As a global pharmaceutical company, Midatech Pharma PLC is committed to advancing and delivering innovative therapies worldwide.

Midatech Pharma PLC has achieved several significant milestones in its history. Firstly, the company successfully completed the acquisition of Zuplenz®, a commercially available cancer supportive care product. Additionally, Midatech received approval for Monosulfiram, an innovative topical treatment for scabies. The company also advanced its internal pipeline, with positive pre-clinical results for its sustained-release biodegradable polymer technology. Furthermore, Midatech obtained regulatory clearance to initiate clinical trials for MTX110, a treatment for childhood brain cancer. These achievements demonstrate Midatech Pharma PLC's dedication to developing and commercializing innovative therapies for unmet medical needs, solidifying its position as a leader in the pharmaceutical industry.

Midatech Pharma PLC is a British pharmaceutical company founded in 2000. With a strong focus on developing and commercializing innovative medicines, Midatech is dedicated to addressing unmet medical needs. Their proprietary drug delivery technologies enable targeted therapies, enhancing the potential for efficacy and reducing side effects. Over the years, Midatech has built a diverse pipeline of products across various therapeutic areas, including oncology and immunology. Committed to advancing healthcare, Midatech continues to collaborate with partners and conduct extensive research to develop novel therapies for the benefit of patients worldwide.

The main competitors of Midatech Pharma PLC in the market include established pharmaceutical companies such as AstraZeneca, Pfizer, and GlaxoSmithKline. These companies also operate in the field of developing and commercializing innovative pharmaceutical products and therapies. Despite facing intense competition, Midatech Pharma PLC has strategically positioned itself through its unique drug delivery technologies and focus on niche therapeutic areas. By continuously advancing its pipeline of drugs, Midatech Pharma PLC aims to differentiate itself in an increasingly competitive market.

Midatech Pharma PLC is primarily active in the biotechnology and pharmaceutical industries.

The business model of Midatech Pharma PLC revolves around developing and commercializing innovative pharmaceutical products. Midatech Pharma specializes in the research and development of targeted therapies to improve the delivery and efficacy of medications. Their focus lies in creating gold nanoparticle-enabled therapies (GNP) for the treatment of various diseases, including cancer and diabetes. By utilizing their expertise in nanotechnology, Midatech Pharma aims to enhance drug delivery to specific disease sites within the body, minimizing side effects and improving patient outcomes. With a strong commitment to research and development, Midatech Pharma strives to bring novel treatment options to patients worldwide.

De K/W-verhouding kan momenteel niet worden berekend voor Midatech Pharma.

De KUV kan momenteel niet worden berekend voor Midatech Pharma.

De AlleAktien Kwaliteitsscore voor Midatech Pharma is 4/10.

De omzet kan momenteel niet worden berekend voor Midatech Pharma.

De winst kan momenteel niet berekend worden voor Midatech Pharma.

Midatech Pharma PLC is a global biopharmaceutical company focused on innovative technologies for the development and marketing of drugs. The company specializes in nanotechnology and uses this technology to develop groundbreaking solutions for drug development. It has two main business areas: core platforms and product development. The core platforms include the nanoparticle platform and the magnetic-responsive platform, which allow for the precise size and shape of drug molecules to be targeted and efficiently delivered in the body. The company is currently involved in the research and development of cancer and diabetes drugs, with multiple candidates in various clinical phases. It has also formed partnerships with other companies and signed agreements to expand the use of its nanoparticle technology in defense and security applications. Moreover, it has expanded its infrastructure through the acquisition of DARA BioSciences, strengthening its presence in the US and improving access to key markets. Overall, Midatech Pharma PLC has achieved a leading position in nanotechnology and is committed to developing drugs for serious diseases like cancer and diabetes. It has also strengthened its infrastructure and presence in key markets through partnerships and acquisitions.

Midatech Pharma keert een dividend van 0 GBP uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Midatech Pharma of het bedrijf keert geen dividend uit.

De ISIN van Midatech Pharma is GB00BKT14T00.

De ticker van Midatech Pharma is MTPH.L.

Binnen de laatste 12 maanden betaalde Midatech Pharma een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Midatech Pharma naar verwachting een dividend van 0 GBP betalen.

De dividendrendement van Midatech Pharma is momenteel .

Midatech Pharma betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Midatech Pharma betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 GBP verwacht. Dit komt overeen met een dividendrendement van 0 %.

Midatech Pharma wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Midatech Pharma van 4-11-2024 ter hoogte van 0 GBP te ontvangen, moest je het aandeel voor de ex-datum op 4-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 4-11-2024.

In het jaar 2023 heeft Midatech Pharma 0 GBP aan dividenden uitgekeerd.

De dividenden van Midatech Pharma worden in GBP uitgekeerd.